Biotech Valuation Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech Valuation

CRSP 56.68

-2.4%

3:59 PM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Biomaven who wrote (2846)	2/7/2001 4:33:54 PM
From: Jibacoa	Read Replies (1) of 52153

NEOT: Has continued to perform well after the news 2 days ago of the planned study with higher doses of Neotrofin in Alzheimer's disease. In the phase II study conducted by Steven Potkin at UCLA, Irvine, the patients that were treated with the higher doses experienced statiscally significant improvement and those were apparently attributed to changes in brain metabolism that were seen using PET scanning and EECG. Those results were presented at the Dec. meeting of the Am.College of Neuropsychopharmacology. As I thik was discussed here, back on Jan.31 they reported significant increased proliferation of stem cells in the brains of adult mice after 24 hrs. of a dose of Neotrofin. NEOT closed today at 4.16 up 30.39% on volume of 1,256,700 just 3/32 below the intra-day H of 4.25 around 10.30AM. If it can close above today's H tomorrow it seems it should be able to test the Jan.4 H at 4.75 (Excuse or disregard the TA garbage) Bernard

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next